What Happened to Prostate Cancer Screening and Treatment After PSA Guidelines Changed?

MedicalResearch.com Interview with:

James T. Kearns, MD Clinical Fellow, Department of Urology University of Washington School of Medicine Seattle, WA 

Dr. Kearns

James T. Kearns, MD
Clinical Fellow, Department of Urology
University of Washington School of Medicine
Seattle, WA

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: The effects of the USPSTF recommendation against prostate cancer screening had not been fully characterized among a younger population, particularly with respect to downstream effects such as prostate biopsy, prostate cancer diagnosis, and treatment for prostate cancer.

We found that PSA testing decreased in the years surrounding the USPSTF recommendation, but we also found a larger proportionate decrease in prostate biopsy, prostate cancer diagnosis, and use of surgery or radiation for the treatment of prostate cancer.

MedicalResearch.com: What should readers take away from your report?

Response: PSA testing declined in the years surrounding the USPSTF recommendation against prostate cancer screening, but it also appears that there was a change in how men who were tested were treated. There were fewer biopsies, and fewer men elected treatment with surgery or radiation. This may suggest that patients and clinicians are being more thoughtful about how to proceed with the information gathered through PSA testing.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: We need to understand how men fare in the long term with regard to prostate cancer in this era of decreased screening. It would also be very interesting to understand the severity of disease in men who chose to treat their prostate cancer versus men who chose to avoid surgery or radiation immediately after diagnosis. 

I have no disclosures regarding this research.

Citation:

PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening

James T. Kearns MD, Sarah K. Holt PhD, Jonathan L. Wright MD, MS, Daniel W. Lin MD, Paul H. Lange MD, John L. Gore MD, MPH

First published: 21 May 2018
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31337

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Last Updated on June 3, 2018 by Marie Benz MD FAAD